Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
Notified -
Globe Newswire4-12-2024, 14:00
Celebrating 25 Years: Trust, Service, and Innovation continue to drive the future of Deriv 15-10-2024, 11:30